@article{aef45c37905b446e9a736068d406cd6b,
title = "Long-term Outcomes of Antiviral Therapy in Patients With Advanced Chronic HBV Infection",
abstract = "Hepatitis B virus (HBV) suppression with nucleot(s)ide analogue therapy reduces the risk of hepatic decompensation and hepatocellular carcinoma (HCC) in patients with advanced liver disease.1 In the present era of potent antiviral therapies, the prognostic significance of the serum HBV DNA level as a biological gradient has substantially diminished; the majority of treated patients achieve virologic suppression.2,3 After control of viremia, a higher baseline fibrosis level is a useful predictor for disease progression.4 Few “prospective” studies on the effects of antiviral agents, especially in chronic hepatitis B (CHB) patients with advanced liver disease, have been reported.",
author = "{Soul Study Group} and Lee, {Hye Won} and Park, {Jun Yong} and Kim, {Sang Gyune} and Tak, {Won Young} and Yim, {Hyung Joon} and Jang, {Byoung Kuk} and Kim, {Moon Young} and Kim, {Byung Ik} and Lee, {Jin Woo} and Yoon, {Ki Tae} and Cheong, {Jae Youn} and Kwon, {So Young} and Kim, {Tae Yeob} and Bae, {Si Hyun} and Seo, {Yeon Seok} and Kwon, {Jung Hyun} and Kim, {Dong Joon} and Kim, {Ja Kyung} and Jeong, {Soung Won} and Sungmin Myoung and Ahn, {Sang Hoon} and Han, {Kwang Hyub}",
note = "Funding Information: Funding This study was supported by a grant of the Korea Healthcare Technology R&D Project, Ministry of Health and Welfare, Republic of Korea (HI10C2020). This investigator-initiated trial was provided the study drug from Bristol-Myers Squibb. Bristol-Myers Squibb had no role in the study design, data collection, and analysis. The authors retain full responsibility. Publisher Copyright: {\textcopyright} 2019 AGA Institute",
year = "2019",
month = dec,
doi = "10.1016/j.cgh.2019.01.044",
language = "English",
volume = "17",
pages = "2811--2813.e1",
journal = "Clinical Gastroenterology and Hepatology",
issn = "1542-3565",
publisher = "W.B. Saunders Ltd",
number = "13",
}